Results 61 to 70 of about 4,690 (200)

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

Frontiers in Immunology
Background CFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF).
Hazel Ozuna, D. Bojja, Santiago Partida-Sanchez, Luanne Hall-Stoodley, Amal O. Amer, R. Britt, Shahid Sheikh, David Frank, Weiyuan Wang, Bum-Yong Kang, Irina Miralda, Samantha L. Durfey, Benjamin T. Kopp   +12 more
semanticscholar   +1 more source

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

BMC Pulmonary Medicine
Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients.
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila   +6 more
doaj   +1 more source

Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A cross-sectional, observational, single-centre study.

Journal of Cystic Fibrosis
BACKGROUND Cystic fibrosis (CF) has been associated with impaired cardiovascular and endothelial function. CF transmembrane conductance regulator (CFTR) modulator therapy, most recently Elexacaftor/Tezacaftor/Ivacaftor (ETI), has led to improved CFTR ...
L. Clayton, A. Shepherd, J. Corbett, M. Perissiou, G. Connett, Julian Legg, M. Allenby, T. Daniels, D. S. Urquhart, K. Mackintosh, M. Mcnarry, Zoe L. Saynor   +11 more
semanticscholar   +1 more source

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation

Health Technology Assessment
Background Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards, Benjamin G Farrar, Kate Ennis, Nicole Downes, Victoria Wakefield, Isaac Mackenzie, Archie Walters, Tracey Jhita   +7 more
doaj   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles

European Respiratory Journal
Extract Clinical trials of the triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) demonstrated unprecedented clinical benefits including improvements in lung function ...
M. Stahl, M. Dohna, S. Graeber, Olaf Sommerburg, D. M. Renz, S. Pallenberg, A. Voskrebenzev, K. Schütz, G. Hansen, F. Doellinger, E. Steinke, Stephanie Thee, Jobst Röhmel, S. Barth, C. Rückes-Nilges, J. Berges, S. Hämmerling, M. Wielpütz, L. Naehrlich, Jens Vogel-Claussen, Burkhard Tümmler, M. Mall, Anna-Maria Dittrich   +22 more
semanticscholar   +1 more source

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor

Therapeutic Advances in Respiratory Disease
Over the past decade, major clinical advances have been made in the healthcare and therapeutic development for cystic fibrosis (CF), a lethal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein.
Vito Terlizzi, Miquéias Lopes-Pacheco
openaire   +3 more sources

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Journal of Clinical Investigation
To the Editor: Elexacaftor/tezacaftor/ivacaftor (ETI) is the most effective modulator drug currently available for most people with cystic fibrosis (PwCF) (1).
Sarah J. Morgan, E. Coulter, Hannah L. Betts, George M. Solomon, J. P. Clancy, S. M. Rowe, David P. Nichols, Pradeep K Singh   +7 more
semanticscholar   +1 more source

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis [PDF]

Australian Prescriber, 2021
openaire   +2 more sources

Advances in the treatment of cystic fibrosis: CFTR modulators

Anales de Pediatría (English Edition)
Cystic fibrosis is a severe genetic disease caused by variants in the CFTR gene. Although it is a multisystem disease, respiratory involvement is the main cause of morbidity and mortality.
Maria Dolores Pastor-Vivero, Jordi Costa i Colomer, Carlos Martín de Vicente, Saioa Vicente-Santamaria, Ruth Garcia Romero, David González Jiménez, Carmen Luna Paredes   +6 more
doaj   +1 more source

Avances en el tratamiento de la fibrosis quística: los moduladores de la CFTR

Anales de Pediatría
Resumen: La fibrosis quística es una enfermedad genética y grave causada por variantes en el gen CFTR. Aunque se trata de una enfermedad multisistémica, la afectación respiratoria es la que produce mayor morbimortalidad.
Maria Dolores Pastor-Vivero, Jordi Costa i Colomer, Carlos Martín de Vicente, Saioa Vicente-Santamaria, Ruth García Romero, David González Jiménez, Carmen Luna Paredes   +6 more
doaj   +1 more source